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Purpose: We performed human, animal, and in vitro studies to examine the potential role of nuclear transport factor 2
(NTF2) in conferring resistance to diabetic retinopathy (DR).
Methods: Blood NTF2 levels were assessed in two groups of patients with type 2 diabetes mellitus. Group P patients had
a history of proliferative DR (PDR), while group N patients did not. The retinal vasculature was examined in diabetic rats
three  months  after  they  received  an  intravitreal  injection  of  a  recombinant  adeno-associated  virus  (rAAV)  vector
overexpressing NTF2 (rAAV2-NTF2). Control rats were treated with rAAV2 only. Rat retinal capillary endothelial cells
(RRCECs) were infected with rAAV2-NTF2, or with a vector expressing siRNA targeted against NTF2, to assess the
effects of overexpression and inhibition of NTF2 on vascular endothelial growth factor (VEGF) expression (mRNA and
protein). 
Results: There was a strong trend for patients with DR to have lower blood NTF2 levels compared to those who did not
have DR (0.10±0.01 versus 0.20±0.08, p=0.079). There was significantly less retinal blood vessel leakage in diabetic rats
infected with rAAV2-NTF2 compared to controls (16.5±2.9 versus 24.7±7.3, p=0.039). These rats exhibited normal retinal
vasculature and blood-retinal barrier function. VEGF expression was inhibited by NTF2 overexpression and stimulated
by NTF2 inhibition, (protein [0.41±0.05 versus 0.23±0.06] and mRNA [0.37±0.04 versus 0.23±0.06] p<0.01 for all).
Conclusions: These finding suggest that NTF2 is a potential mediator of retinal vasculature integrity. NTF2 may act by
altering VEGF expression, thereby influencing the development of DR in patients with diabetes mellitus.
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Diabetic retinopathy (DR) and consequent vision loss or
impairment is a common complication of type 2 diabetes
mellitus (DM). To date, no effective therapy exists to treat this
associated vision loss. Lack of glucose control and the chronic
nature of the disease are key risk factors, but DR also contains
a hereditary component. The aldose reductase (ALR2) gene
(allele z-4) has been linked to the occurrence of DR [1]. Wang
and colleagues [2] found that Chinese patients with type 2 DM
exhibited phenotypic differences in terms of risk factors for
DR,  and  that  ALR2  was  associated  with  microvascular
complications.  A  study  of  Mexican  Americans  with  DM
revealed that retinopathy was linked to two chromosomes
[3], while Suzuki et al. [4] reported that apolipoprotein was
associated with the occurrence of DR. Other studies indicate
that  vascular  endothelial  growth  factor  (VEGF),  genetic
polymorphisms,  and  mitochondrial  rRNA  genetic
polymorphisms may contribute to DR pathology [5,6].
The onset of DR among DM patients is variable. Some
patients acquire DR as soon as they develop DM, while others
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either do not exhibit symptoms, or have very mild symptoms
even many years after the onset of DM [7]. An epidemiologic
study of American patients with a 20-year history of DM
revealed that 80% had developed DR [8]. Evidently there is a
distinct cohort of individuals with DM who are somehow
“immune” to the onset of DR. These findings suggest the
existence  of  a  genetic  polymorphism  that  protects  retinal
blood vessels from the damage associated with DM. Given
this  and  the  knowledge  that  no  current  medication  can
effectively control the occurrence and development of DR, it
would seem pertinent to search for and try to identify genes
that may be involved in conferring resistance to DR.
Nuclear transport factor 2 (NTF2) is a small guanosine
5′-diphosphate (GDP) Ran binding protein found in all human
cell types. It is involved in regulating multiple processes,
including cell cycle, immunoreactions, and apoptosis [9-11].
The main function of NTF2 is to facilitate transport of certain
proteins  into  the  nucleus  via  interaction  with  nucleoporin
FxFG  [12,13].  NTF2  also  works  as  a  GDP-dissociation
inhibitor to mediate the GDP-Ran gradient, which is also
involved  nucleocytoplasmic  transport  [14-16].  The
importance of NTF2 is illustrated by the findings that deletion
of this gene results in lethality [17]. With regards to the eye,
it has been reported that partial deletion or mutation of theTABLE 1. SUMMARY OF SIGNIFICANT DIFFERENTIAL GENE EXPRESSION AS DETERMINED BY MICROARRAY ANALYSIS.
Gene Description p-value
213726_x_at nf66f09.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE:924905 3′ similar to gb:X79535 tubulin beta-2
chain (human); mRNA sequence.
0.00988
209458_x_at hemoglobin, alpha 2 0.00985
206208_at carbonic anhydrase IV 0.00981
1558459_s_at MRNA; cDNA DKFZp686D21117 (from clone DKFZp686D21117) 0.00923
201230_s_at ariadne homolog 2 (Drosophila) 0.00895
226975_at hypothetical protein FLJ25070 0.00895
1553588_at NADH dehydrogenase, subunit 3 (complex I); go_component: mitochondrial inner membrane [goid 0005743]
[evidence P] [pmid 9878551]; go_component: respiratory chain complex I (sensu Eukarya) [goid 0005747] [evidence
NAS]; go_component: mitochondrion [goid 0005739] [evidence IEA]; go_function: NADH dehydrogenase
(ubiquinone) activity [goid 0008137] [evidence NAS] [pmid 9878551]; go_function: oxidoreductase activity [goid
0016491] [evidence IEA]; go_process: mitochondrial electron transport, NADH to ubiquinone [goid 0006120]
[evidence NAS] [pmid 9878551]; Homo sapiens NADH dehydrogenase 3 (MTND3), mRNA.
0.00892
226434_at hypothetical protein MGC22793 0.0084
201788_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 0.00824
223440_at lin-10 protein homolog 0.00802
243954_at Hypothetical protein LOC285286 (LOC285286), mRNA 0.00781
205844_at vanin 1 0.00673
228460_at zinc finger protein 319 0.00671
236012_at proteasome (prosome, macropain) inhibitor subunit 1 (PI31) 0.00663
233690_at CDNA: FLJ23090 fis, clone LNG07119 0.00576
202397_at nuclear transport factor 2 0.00542
224776_at putative lysophosphatidic acid acyltransferase 0.00529
201378_s_at NICE-4 protein 0.00515
223365_at DEAH (Asp-Glu-Ala-His) box polypeptide 37 0.00469
217232_x_at Homo sapiens mutant beta-globin (HBB) gene, complete cds 0.00402
211745_x_at hemoglobin, alpha 2 0.00385
219226_at CDC2-related protein kinase 7 0.00286
225819_at transforming growth factor beta regulator 1 0.000514
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NTF2 gene may cause heteroplasia in the eyes of Drosophila
[17]. It has been further suggested that partial loss of NTF2
function might alter the nuclear import of Ran proteins during
the immune response and that the loss of functional alleles
may be associated with the strong eye phenotype [18].
In this study,we obtained blood samples from patients
who suffered DM, but not proliferative DR (PDR), and from
patients who suffered DM and PDR. RNA was extracted from
these samples and subjected to microarray analysis to search
for genes differentially expressed between the two patient
groups and hence perhaps associated with DR. One of these
was NTF2 (Table 1).
The aim of the current study was to determine if NTF2
plays a role in conferring resistance to DR. A series of studies
were performed. NTF2 gene expression was determined in a
cohort of DM patients divided into those with PDR and those
without. In vivo studies with diabetic rats and in vitro studies
using rat retinal capillary endothelial cells (RRCECs)were
performed  to  assess  the  effects  of  overexpression  and
inhibition  of  NTF2  expression  on  retinal  vasculature  and
inhibition of retinal damage.
METHODS
Human study: Patients were classified into two groups: those
without PDR (group N) and those with PDR (group P). Group
N patients had a 20 to 25 year history of DM without PDR as
confirmed  by  retinal  photography  and  fluorescein
angiography. Group P patients had a 20 to 25 year history of
type 2 DM with active PDR in both eyes as confirmed by
retinal photography. 59 patients in both groups were of similar
age  (average  age  67.3  years  old),  weight,  ethnicity  (Han
Chinese), equal gender distribution and resided in or around
Guangzhou City, China. Living standards of patients in both
groups were similar. All patients had been on insulin therapy
for approximately two years. Glucose levels before and after
meals were strictly controlled in Group N but not in Group P.
The  diagnosis  of  PDR  was  made  in  accordance  with
international standards. Patients with malignant tumors, other
hereditary  diseases,  severe  infectious  diseases  (i.e.,
tuberculosis, hepatitis B) by biochemical examination and
asked about the disease history, and hypertension or unstable
critical condition were excluded. A total of 22 and 37 patients
met the inclusion criteria for groups N and P over a period of
14 months. Blood samples (2.5 ml) were obtained from 20
patients (we selected) in each group for microarray analysis.
Thereafter, six blood samples from each group of patients
were selected, along with samples from a cohort of healthy
volunteers controls (the NO group, 6 patients were recruited,
they live in Guangzhou China, and average age of 68.5 years,
the blood samples was frozen in −20 °C), for evaluation of
NTF2 gene expression.This research was approved by the ethics committee of
Zhongshan  Ophthalmic  Center,  Sun  Yet-Sun  University.
Each patient signed a consent statement before entering the
study.
Quantitative  real  time  PCR  evaluation  of  NTF2  gene
expression:  Total  RNA  was  isolated  from  patient  blood
samples using Trizol reagent (Gibco, Los Angeles, CA) and
purified by Qiagen RNeasy Mini Kit (Qiagen, Venlo, The
Netherlands).  Synthesis  of  cDNA  was  performed  using  a
Super-Script  II  cDNA  synthesis  Kit  (Invitrogen  Inc.,
Carlsbad, CA). Real-time PCR (RT–PCR) was performed
using a Hotstar Taq polymerase kit (Qiagen) with SYBR
Green technology (Applied Biosystems Inc., Foster City, CA)
according to the manufacturer’s instructions. Relative gene
expression was determined. The primers used to detect 384
bp NTF2 are described in Table 2.
Construction and packaging of rAAV2-NTF-2: The coding
sequence for NTF2 was obtained from the Sprague-Dawley
(SD) rat cDNA bank and was extended using Golden Taq
(Tiangen  Biotech,  Beijing,  China).  The  method  for
construction  and  packaging  rAAV2-NTF-2  has  been
described previously [19]: The oligonucleotide upper primer
are described in Table 3, polymerase chain reaction (PCR)
amplification was performed in a final volume of 50 μl. The
following temperature conditions were used for the reactions:
3 min initial denaturation at 94 °C, then 32 cycles for 30 s
denaturation at 94 °C; 30 s annealing at 56 °C, synthesis for
1 min at 72 °C. The amplified product was subcloned directly
into  vector  pGEM-T.  Gene  sequence  was  verified  by
dideoxynucleotide sequencing. Digestion of the recombinant
plasmid pGEM-T-NTF2 with EcoRI acquired the cDNA of
NTF2 extracellular domain which was subcloned into the
EcoRI site of the gene therapy vector pSNAV-2. Recombinant
plasmid was examined by restriction enzyme digestion and
named pSNAV- 2/NTF2.
Transfection of baby hamster kidney (BHK-21) cells with
cells with pSNAV-NTF-2 was performed in six-well plates
using  a  Lipofectamine  2000  kit  (Invitrogen).  These  cells,
named BHK/NTF-2, were then transferred and cultured in a
110 mm×480 mm flask (Wheaton Inc., Wheaton, IL), then
TABLE 2. QUANTITATIVE REAL TIME PCR EVALUATION OF NTF2 GENE EXPRESSION.
Gene Primer (5′-3′) PCR annealing temp (°C)
NTF2 AGCTTAAGGCGGATGAAGACC 58
GAGGAGGAAACAGCGTGAGTG
β-actin CTTTTAGGATGGCAAGGGACT 58
TGGAACGGTGAAGGTGACA
TABLE 3. CLONING AND SEQUENCING OF THE RAT NTF2 GENE.
Gene Primer (5′-3′) PCR annealing temp (°C)
NTF2 GGAATTCATGGGAGACAAGCCAATTG 56
GGAATTCTCAGCCGAAGTTGTGC
TABLE 4. THE RNAI NTF2 SEQUENCE.
Primer Sequence
Sense GATCCAAGCCAATTTGGGAGCAGATTTTCAAGAGAAATCTG
CTCCCAAATTGGCTTTTTTTTACGCGTG
Antisense ATTCACGCGTAAAAAAAAGCCAATTTGGGAGCAGATTTCTC
TTGAAAATCTGCTCCCAAATTGGCTTG
TABLE 5. QUANTITATIVE REAL TIME PCR EVALUATION OF NTF2 AND VEGF EXPRESSION.
Gene Primer (5′-3′) PCR annealing temp (°C)
NTF2 AAAGAACATCAATGACGCTTGG 57
GGAGCATCTGGAGGAGATAGGA
β-actin CTGGGTATGGAATCCTGTGG 58
TCATCGTACTCCTGCTTGCTG
VEGF TCTTCAAGCCGTCCTGTGTG 58
ACAGTGAACGCTCCAGGATTTA
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863infected  with  HSV1-rc/ΔUL2  (Benyuan  Zhengyang  Inc.,
Beijing,  China;  MOI=0.1)  when  the  cell  number  reached
8×108. The cells were then divided into 250 ml Fernbach
culture flasks for further purification after 48 h culture.
The  rAAV2-NTF-2  virus  was  purified  and  identified
using  RT–PCR  as  described  previously  [19].  The  titer  of
rAAV2-NTF-2 (virus genome/ml [vg/ml]) was detected using
in situ hybridization with a digoxin-labeled cytomegalovirus
probe. The final titer was 1×1012 virus genomes/ml.
In vivo study: overexpression of the NTF2 gene in the rat
retina:  Obtained  from  the  animal  center  of  Huazhong
University of Science and Technology were 60, two-month-
old male Sprague Dawley rats, weighing between 150 and 200
g. Rats maintained in an cleaning environment for two weeks
before experimentation. Rats were randomly divided into two
groups, A and B, and containing 30 rats per group. Each rat
in  Group  A  received  an  intravitreal  injection  of  purified
rAAV2-NTF2  in  either  the  left  or  right  eye  (determined
randomly). Rats in Group B were injected with rAAV2 only.
Diabetes  animal  model  were  Constructed  after  rAAV2
treatment one month: after fasting for 12 h [20], the rats were
injected with a single dose of streptozotocin (STZ; 65 mg/kg
intraperitoneal injection in 0.01 M citrate buffer with a pH of
4.5). Nondiabetic control mice received citrate buffer only.
Fasting plasma glucose was examined after 3 days of STZ
injection,  and  diabetes  was  confirmed  by  fasting  plasma
glucose  value  of  16.7  mmol/l  or  higher  using  Touch™
Glucometer  (Boehringer  Mannheim  Diagnostics,
Indianapolis, IN). Retinal integrity was assessed two months
later.
Assessment of retinal blood vessel leakage—Retinal
vascular  permeability  was  determined  by  assessing
fluorescein isothiocyannate-dextran (FITC- dextran) [21-23]
and  Evans  Blue  (EB)  retinal  leakage  [24].  Rats  were
anesthetized  by  intraperitoneal  injection  of  50  mg/kg
ketamine and 20 mg/kg chlorpromazine. Next, a 100 mg/kg
solution of FITC-dextran solution (Sigma, St Louis, MO) or
45 mg/kg of 3% EB (Sigma) was injected via the tail vein. The
chest was opened after 2 h and an infusion tube connected with
a 14G blunt needle was inserted into the left ventricle. The
right atrial appendage was cut open, and the heart was infused
with fluid contained 0.05 M 1% paraformaldehyde citrate
buffer, pH 3.5, at 250 ml/kg bodyweight. Infusion height was
160  cm,  resulting  in  an  equivalent  infusion  pressure  of
120 mmHg. The infusion was maintained for 2 min to remove
any remnant dye in the blood vessels. The eyes of rat were
then removed, and the retina was dissected and mounted to
determine  retinal  blood  vessel  leakage  (FITC-dextran
leakage) by microscopy.
To assess EB leakage, we dried dissected retinas under
vacuum (45 °C for 5 h). The retinal dry weight was recorded.
The difference in retinal weight between diabetic rats injected
with rAAV2-NTF2 and controls was compared. Next, 120 μl
formamide was added and the solution placed in a 70 °C water
bath for 18 h. The sample was then centrifuged at 7,280 xg for
30 min to separate the dye from the protein. The absorbance
of the 50 μl filtered fluid was detected at wavelengths of 620
nm and 740 nm using a Beckman DU-640 spectrophotometer
(Beckman Coulter, Fullerton, CA). The net absorbance was
calculated by subtracting the absorbance at 740 nm from that
at 620 nm. The concentration of dye was calculated from a
standard curve (determined for each measurement) of EB in
formamide. Samples were analyzed in triplicate and the mean
calculated. The dry weight of the retina (mg) was used to
standardize dye content and values are presented in ng/mg.
The formula was as follows:
EB content in the retina (ng/mg)=[EB concentration in
formamide (ng/μl)×120 (μl)]/dry weight of the retina (mg)
In vitro studies: inhibition of NTF2 expression using siRNA:
In  vitro  cultured  RRCECs  were  prepared  as  previously
described [25]. Briefly, rat eyes were cut circumferentially
1.5 mm posterior to the limbus, and the retinas were harvested
and homogenized by two gentle up-and-down strokes in a 15
ml homogenizer (Dounce; Bellco Glass Co., Vineland, NJ).
The homogenate was filtered. The remaining retentate was
digested in 0.066% collagenase for 45 min at 37 °C. The
homogenate was centrifuged (1,000x g for 10 min), and the
pellet was resuspended in human serum-free endothelial-basal
growth  medium  Invitrogen-Gibco,  Grand  Island,  NY),
supplemented  with  20%  fetal  bovine  serum,  50  U/ml
endothelial cell growth factor (Sigma-Aldrich). Cells were
cultured in fibronectin-coated dishes and incubated at 37 °C
in a humidified atmosphere containing 5% CO2. Cultured
Figure 1. NTF2 expression was significantly lower in patients with
PDR. Expression of NTF2 mRNA as determined by real-time PCR
in patients with type 2 diabetes mellitus (DM) and proliferative
diabetic retinopathy (PDR, group P), DM without PDR (group N)
and healthy volunteers (group NO). Asterisk indicates significance
between groups difference (p<0.05).
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864RRCECs were transfected with rAAV2-NTF2, or rAAV2-
GFP.  Cells  were  plated  in  24  well  culture  plates,  grown
overnight to 70%–80% confluence. Cells were then washed
twice with serum-free human endothelial-serum-free medium
basal growth medium. Next, 1×109 vg/ml rAAV2-NTF2 was
added to each well in the experimental group while 1×109 vg/
ml rAAV2 only was added to control wells. rAAV2-GFP was
added to six separate wells to monitor infection efficiency
(subsequently found to approximate 93%).
A vector containing siRNA for NTF2 was constructed by
cloning the double stranded sequence into the RNAi-Ready
pSIREN-RetroQ  ZsGreen  vector  (pSIREN  vector;  BD
Biosciences, Franklin Lakes, NJ) to yield the pSIREN-NTF2
siRNA vector. The NTF2 sequences (obtained from Qiagen)
were  described  in  Table  4.  RRCECs  were  infected  with
pSIREN-NTF2  siRNA  or  pSIREN  vectors  using
Lipofectamine. Real time PCR and western blot analyses were
performed to examine the RNA and protein expression levels
of NTF2 and VEGF two days after infection.
Quantitative  real  time  PCR  and  western  blot
evaluation  of  NTF2  and  VEGF  gene  and  protein
expression—Total RNA was isolated from RRCECs using
Trizol reagent (Gibco, Los Angeles, CA) and purified by
Qiagen RNeasy Mini Kit (Qiagen, Venlo, The Netherlands).
Synthesis of cDNA was performed using a Super-Script II
cDNA synthesis Kit (Invitrogen Inc.). Real-time PCR was
performed using a Hotstar Taq polymerase kit (Qiagen) with
SYBR Green technology (Applied Biosystems Inc., Foster
City,  CA)  according  to  the  manufacturer’s  instructions.
Relative gene expression was determined. The primers were
described  in  Table  5.  Total  protein  was  extracted  from
RRCECs using bicinchoninic acid. Isolated protein was mixed
with loading buffer, denatured for 6 min at 60 °C, cooled,
centrifuged for 5 min, and then separated by sodium-dodecyl
sulfate  PAGE  (SDS–PAGE).  Antibodies  directed  toward
NTF2 and VEGF (Santa Cruz Biotechnology Inc., Santa Cruz,
CA) were used to probe the proteins. A secondary antibody
goat  anti-mouseIgG-HRP  (1:1,000  dilution,  Santa  Cruz
Biotechnology Inc., Santa Cruz, CA) was applied, and the
signal  was  revealed  by  chemiluminescence.  The
polyvinylidene fluoride membranes were reused to detect β-
actin  (internal  control)  by  incubating  with  a  mouse  anti-
human actin antibody (Gene Co, Hong Kong, China). The
bands detected were analyzed by automatic image analysis,
and the integrated optical density (OPTDI) of each protein
band was normalized to the OPTDI value of the corresponding
β-actin band from the same sample.
Statistical analysis: Normally distributed data were compared
by independent two samples t-test or one-way ANOVA where
appropriate.  When  a  significant  difference  was  detected
between  groups  differences  were  detected,  multiple
comparisons of means were performed using the Bonferroni
procedure,  with  type-I  error  rate  at  a  maximum  of
0.017(0.05/3) adjustment. Statistical analyses were performed
using SPSS 15.0 statistics software (SPSS Inc., Chicago, IL),
Figure 2. Retinal sections from diabetic
rats  infused  with  fluorescein
isothiocyanate.  Representative  images
from rAAV2-infected rats was shown
on A and B. Representative images from
rAAV2-NTF2-infected rats were shown
on  C  and  D.  Decreased  blood  vessel
leakage  was  apparent  in  retinas  from
group  B  rats  (NTF2  overexpression).
Scale bar=50 μm for A and C, 100 μm
for B and D.
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Data are presented as the mean±standard deviation (SD).
RESULTS
NTF2 expression in patients: There was a significant overall
difference in NTF2 gene expression among the groups (NO,
N, and P). NTF2 expression was lower in group N patients
compared  to  NO  (control),  however  this  difference  was
insignificant (0.20±0.08 versus 0.26±0.09, p=0.479; Figure
1).  NTF2  expression  was  significantly  higher  in  normal
compared to group P patients (0.26±0.09 versus 0.10±0.01;
p=0.004).  There  was  no  significant  difference  in  NTF2
expression between group N and P patients.
Effect of NTF2 overexpression on retinal blood vessel leakage
in rats with DM: The FITC-dextran blood vessel leakage area
was significantly decreased in rats treated with rAAV2-NTF2
compared to in control rats (11.3±1.5% versus 23.7±2.8%;
p<0.05). Representative images demonstrating retinal leakage
of FITC dye can be seen in Figure 2.
There was significantly less EB content in retinas from
rAAV2-NTF2 injected as compared to control rats (16.5±2.9
ng/mg retinal dry weight versus 24.7±7.3 ng/mg retinal dry
weight; p=0.039).
Effects  of  NTF2  overexpression  and  downregulation  on
VEGF expression in RRCECs: Real time PCR revealed that
infection  of  RRCECs  with  rAAV2-NTF2  resulted  in
significant upregulation of NTF2 mRNA (0.77±0.05 versus
0.51±0.02,  p<0.01),  In  contrast,  VEGF  mRNA  were
significantly  decreased  in  these  cells  (0.19±0.03  versus
0.28±0.03,  p<0.01).  NTF2  mRNA  were  significantly
decreased following transfection with pSIREN-NTF2 siRNA
(0.27±0.06 versus 0.55±0.08; p<0.01). While VEGF mRNA
were significantly increased in these compared to control cells
(0.37±0.04 versus 0.23±0.06; p<0.01). Western blot analyses
confirmed  that  Infection  of  RRCECs  with  rAAV2-NTF2
resulted  in  significant  upregulation  of  NTF2  protein
expression  (1.03±0.20  versus  0.55±0.13,Figure  3A  and
Figure  4B;  p<0.01).  In  contrast,  VEGF  protein  levels
(0.76±0.14 versus 1.26±0.17) were significantly decreased in
these cells (Figure 3B and Figure 4D; p<0.01). NTF2 protein
expression  levels  were  significantly  decreased  following
transfection  with  pSIREN-NTF2  siRNA  (Figure  3C  and
0.46±0.07  versus  1.01±0.10;  Figure  4F;  p<0.01).  While
VEGF protein levels were significantly increased in these
compared to control cells (Figure 3D and 0.41±0.05 versus
0.23±0.06; Figure 4H; p<0.01)
DISCUSSION
The results of this study suggest that NTF2 may be involved
in  mediating  DR  in  patients  with  DM.  Several  lines  of
evidence  support  this  assertion.  We  found  NTF2  mRNA
Figure  3.  Effects  of  NTF2  levels  on
NTF2  and  VEGF  mRNA  expression.
Overexpression of NTF2 by transfection
of  rAAV2-NTF2  increased  the
expression level of NTF2 but reduced
the  expression  of  VEGF  (A,  B).
Downregulation  of  NTF2  by
transfection  with  pSIREN-NTF2
siRNA  reduced  NTF2  expression  but
increased VEGF expression (C, D). The
experiments  were  performed  in  rat
retinal  capillary  endothelial  cells.
Asterisk  (*)  indicates  a  significant
difference between groups (p<0.05).
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compared to those without PDR. Even though the difference
in humans was not statistically significant, we also found
overexpression of NTF2 in diabetic rats was associated with
decreased indices of retinal damage. Findings from our in
vitro studies of RRCECs, in which NTF2 expression was
Figure 4. Effects of NTF2 expression on
NTF2  and  VEGF  protein  levels.
Overexpression  of  NTF2  by
transfection  with  rAAV2-NTF2
increased NTF2 protein expression but
reduced  VEGF  protein  level  (B,  D).
Downregulation  of  NTF2  by
transfection  with  pSIREN-NTF2
siRNA  inhibited  NTF2  protein
expression but increased VEGF protein
level  (F,  H).  The  experiments  were
performed  in  rat  retinal  capillary
endothelial  cells.  Representative
western blots were shown for the effects
of  NTF2  overexpression  and
downregulation  on  NTF2  (A,  E)  and
VEGF  (C,  G)  preotein  expression.
Asterisk  (*)  indicates  a  significant
difference between the groups (p<0.05).
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modulates VEGF expression. This is an important observation
given that NTF2 may play a role in mediating the progression
of DR and suggests the need for further studies, particularly
in humans.
DR is among the most prevalent complications associated
with DM. Hence, it is closely related to DM. Several studies
have suggested that there is a genetic component to PDR [2,
3,6,26]. It would appear that genes involved help maintain
functionality  of  the  retinal  blood  vessels  and  protects  the
surrounding tissue from DM-related damage.
At the beginning of study, we examined NTF2 expression
levels in patients, who had DM with or without PDR for 20–
25 year. Potential confounding factors (e.g., age, gender, types
of illness, and living conditions) were eliminated due to a strict
selection  and  exclusion  criteria  of  patients.  Hence  the
differentiating factor between the 2 groups of patients was the
presence or absence of PDR. We found that NTF2 levels in
patients with PDR were significantly lower than in normal
healthy  individuals  (NO)  While  there  was  no  significant
difference detected between the patient groups, there was a
strong trend for patients with PDR to have lower NTF2 levels
(p=0.079). This lack of a difference between these groups may
be  a  reflection  of  the  relatively  small  sample  size.
Nevertheless, this finding encouraged us to further examine
the importance of NTF2 with regards to the development of
DR.
Findings from  a  study by  Minakhina  and  colleague s
[17]  have interesting parallels to our own. These researchers
found that low NTF2 gene expression resulted in abnormal
eye growth in Drosophila. Higher NTF2 gene expression was
required  to  maintain  normal  eye  growth.  The  number  of
compound eyes was significantly decreased in Drosophila
with reduced as compared to normal NTF2 expression. The
decreased  frequency  of  compound  eyes  in  low  NTF2
expression Drosophila may have been due to dysplasia of
blood vessels in the eye.
Given  that  lower  VEGF  expression  is  thought  to  be
associated with DR resistance [27], it is plausible that NTF2
may  offer  protection  from  DR  by  depressing  VEGF
expression. Indeed our findings suggest that this may be the
case (at least in part). We found that expression of NTF2 in
RRCECs was inversely related to VEGF expression (both
mRNA and protein). Precisely how NTF2 might influence
VEGF expression is unclear. Further studies examining the
effects of NTF2 on downstream inflammatory and vascular
factors are warranted to clarify this point. Certainly, NTF2
may influence other mediators of DR aside from VEGF.
In summary, the findings from our study implicate NTF2
as a potential mediator of retinal vasculature protection and
suggest that expression levels of this gene may dictate, at least
to some extent, development of PDR in patients with DM. Our
findings also suggest that NTF2 may exert such effects by
altering VEGF expression. Further studies are warranted to
examine potentials pathways through which NTF2 may be
exerting such effects.
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